Sign in

CIK 0002020932 · Non-accelerated filer<br>Emerging growth company

AgomAb Therapeutics NV

Sign in to watch
Ticker
AGMB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
Belgium
Entity type
other
Phone
32 3 302 35 30
Business address
POSTHOFLEI 1/6, ANTWERPEN, Belgium, 2600
  1. 4 Open-market buy Director bought 15,000 shares at an average $6.90 ($103,500)
  2. 4 Open-market buy Director bought 10,000 shares at an average $8.88 ($88,800)
  3. 6-K Event Report of Foreign Issuer
  4. 4 Open-market buy Director bought 5,000 shares at $8.90 ($44,500)
  5. 4 Open-market buy Director bought 10,000 shares at an average $8.64 ($86,350)
  6. 4 Open-market buy Chief Financial Officer bought 10,000 shares at an average $8.59 ($85,940)
  7. 4 Open-market buy Chief Executive Officer bought 11,000 shares at an average $8.58 ($94,380)
  8. 6-K Event Report of Foreign Issuer
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 3 Insider Initial Statement of Ownership
  12. 3 Insider Initial Statement of Ownership
  13. 6-K Event Report of Foreign Issuer
  14. 6-K Event Report of Foreign Issuer
  15. 6-K Event Report of Foreign Issuer
  16. 6-K Event Report of Foreign Issuer
  17. 6-K Event Report of Foreign Issuer
  18. 6-K Event Report of Foreign Issuer
  19. SCHEDULE 13G Stake Statement of Beneficial Ownership
  20. SCHEDULE 13G Stake Statement of Beneficial Ownership

Page 1 of 3 · 49 filings